Latest Dividends And Share Buybacks News

Lloyds Banking Group reported a robust 2025 performance with a 12% rise in statutory profit before tax and upgraded its 2026 guidance, underpinned by strong loan growth and digital innovation. The Group also announced significant shareholder returns totalling £3.9 billion, including dividends and a share buyback programme.

Perseus Mining has expanded and refinanced its corporate debt facility to US$400 million, significantly enhancing its liquidity position to over US$1.2 billion. This move positions the gold miner strongly for future growth and shareholder returns.

GTN Limited faced a tough FY25 with declining revenue and earnings but responded with strategic cost-saving initiatives and strong shareholder returns.

Solvar Limited reported solid FY25 results with profit growth, a significant dividend hike, and a positive outlook for FY26 driven by loan originations and commercial lending expansion.

DPM Metals delivered record third quarter financial results driven by strong free cash flow and adjusted net earnings, while its recent acquisition of Adriatic Metals' Vareš operation promises higher-than-expected production in 2026.

Dyno Nobel reported a modest revenue dip but a solid 5.6% rise in net profit excluding one-off items for FY25, completing key divestments and advancing its transformation program.

Ramelius Resources unveils a fully funded five-year growth plan targeting over 500,000 ounces of gold production annually by FY30, backed by major plant upgrades and strong free cash flow projections.

Sequoia Financial Group reported a robust FY25 with a 13.7% rise in EBITDA and a 44% jump in funds under advice, underpinned by strategic restructuring and technology investments.

Katana Capital Limited reported a solid increase in net profit for FY2025 alongside a fully franked dividend and a strategic share buyback, signaling confidence despite lower revenue.

Australian Clinical Labs delivered solid FY25 financial results with revenue up 6.4% and EBIT rising 8.7%, underpinned by operational efficiencies and strategic innovation. The company’s FY26 guidance signals continued growth amid evolving market conditions and government fee pressures.

Australian Clinical Labs reported robust FY25 financial results with revenue and earnings growth, alongside a strong dividend payout and positive outlook for FY26.

WAM Income Maximiser Limited has reported a profitable first half since its April 2025 IPO, declaring its inaugural fully franked monthly dividend and setting guidance for dividend growth. The company’s diversified portfolio of ASX300 equities and investment grade corporate debt has delivered promising returns, underpinning its income and capital growth objectives.